Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...